

MLA subsidiary chosen to help develop canine cancer treatment

- **MediVet division to work with University of Kentucky researchers to develop canine cancer vaccine treatment**
- **Company chosen due to success with proprietary adipose-derived stem cell and platelet rich plasma treatments**
- **Cancer affects approximately 50% of dogs over 10 years of age¹ – large potential market**

Sydney, 19 January 2015: Human and animal healthcare company Medical Australia Limited (“MLA”, the “Company”) is pleased to announce that a division of its US-based subsidiary, MediVet America LLC (recently rebranded as MediVet Biologics LLC), has been chosen to partner with prominent researchers from the University of Kentucky’s College of Medicine to assist with developing a revolutionary canine cancer vaccine treatment.

Researchers from the University have selected MediVet Biologics to partner with them due to its proven track record in developing and delivering a range of advanced and unique treatments in the animal healthcare field, in particular its proprietary adipose-derived stem cell and platelet rich plasma treatments, which are starting to see greater acceptance and uptake in both the US and Australian markets.

Leading researcher, John Yannelli PhD, has spent over 20 years conducting successful NIH-funded clinical trials. Dr Yannelli has published nearly 100 academic articles and book chapters on the immunotherapy of human cancer and continues research to improve immunotherapeutic approaches to treat the disease. With this strong knowledge base and building on breakthroughs in researching and developing cancer treatments, this outstanding partnership now extends its efforts toward developing an effective and affordable personalised cancer vaccine service for veterinary medicine.

The canine cancer vaccine treatment would offer superior outcomes for dogs suffering from the disease, as a replacement for existing remedies such as surgery, radiation or chemotherapy, all of which often cause undesirable side effects. The treatment would also have a large potential market, with the incidence of cancer in dogs over 10 years of age being approximately 50%¹.

The University and MediVet Biologics are now launching a major trial and will collaborate closely to further develop a specific cancer vaccine service, in which tissue samples will be processed into an individualised therapeutic vaccine. An article outlining the technical details of the research and trial can be found on [the MediVet Biologics website](#) and in the February issue of VPN (*Veterinary Practice News*).

Medical Australia’s Chief Executive Officer, Mr Darryl Ellis, commented: “The decision by the University of Kentucky to partner with MediVet Biologics in this exciting and ground-breaking research is a huge vote of confidence in our team, our technology and the unique range of treatments that we offer the animal healthcare industry.”

“This initiative is part of a broader research and development program within the MediVet Biologics subsidiary, along with the further development and marketing of our veterinary and stem cell business in the United States with more announcements to come throughout the year.”

“We look forward to updating shareholders on these initiatives, along with our progress in the human healthcare business in the weeks and months to come.”

¹ Source: http://www.wearethecure.org/more_cancer_facts.htm

- ENDS -



For more information contact:

Darryl Ellis
Chief Executive Officer
Medical Australia
Ph: +61 2 9466 5300

Media please contact: Adam Jarvis, Six Degrees Investor Relations: +61 424 297 736

ABOUT MEDICAL AUSTRALIA LIMITED

Medical Australia Limited (ASX: MLA) is a human and animal healthcare company engaged in the manufacture, distribution and sale of a broad range of medical and veterinary devices used by healthcare facilities, critical care services and veterinarians in global markets. The Company is a leader in Intravenous (IV) Medication Delivery Systems, Surgical Irrigation, Suction and Oxygen Therapy, Safety Sharps Collection and Reuse Prevention and specialised Diagnostic and Laboratory Equipment. Our products are used in three broad areas of healthcare, Human Health; Biological Collection, Processing and Laboratory; and Animal Health. Through the acquisition of MediVet Pty Ltd Medical Australia now has proprietary ownership of technology for regenerative medicine including stem cell therapy for domestic animals and the equine industry. Medical Australia's animal health business is now represented in major countries and regions such as Canada, USA, Great Britain, Continental Europe, Australia and the Asia Pacific Region, including a 60.5% interest in MediVet America LLC.